Actively Recruiting
Study of New Hormone Therapy Combined With Local Treatment Using PSMA PETCT in Men With Metastatic Hormone-Sensitive Prostate Cancer
Led by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Updated on 2026-03-25
192
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating treatment options for metastatic hormone sensitive prostate cancer mHSPC, focusing on combining novel hormone therapy NHT with local treatment. The study aims to clarify how to create more personalized treatment plans, especially using prostate-specific membrane antigen PSMA PETCT scans to identify active cancer lesions after initial therapy. This study is a Phase 2 trial evaluating the effects of adding local treatment to NHT in patients with remaining active lesions seen on PSMA PETCT after 8 months of hormone therapy. Participants will receive gonadotropin releasing hormone analog GnRHa plus NHT, which may include drugs like abiraterone, apalutamide, or rezvilutamide, chosen based on clinical guidelines. After 8 months of this therapy, PSMA PETCT scans will reassess active lesions. Patients with persistent active lesions will be randomized to continue NHT alone or to receive NHT combined with local treatments such as radiotherapy, orthopedic surgery for bone lesions, or high-energy focused ultrasound for lymph node lesions. Treatment plans are tailored by researchers according to patient conditions. During the study, participants will be monitored to measure progression-free survival from enrollment until 12 weeks after treatment. Assessments include clinical evaluations and imaging with PSMA PETCT to track disease status. The study will provide insights into whether adding local treatment delays disease progression and improves survival for mHSPC patients. The trial is sponsored by Shanghai General Hospital and will run until December 2028.
CONDITIONS
Brief Title
Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients
Research Team
B
Bangmin Han, Doctor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here